StartWXXWY • OTCMKTS
add
Wuxi Biologics Cayman ADR
Seneste lukkekurs
3,75 $
Dagsinterval
3,70 $ - 3,90 $
Årsinterval
2,58 $ - 11,17 $
Markedsværdi
61,29 mia. HKD
Gns. volumen
43,78 t
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
| (CNY) | jun. 2024info | År til år-ændring |
|---|---|---|
Indtægt | 4,29 mia. | 0,97 % |
Driftsudgifter | 765,14 mio. | 21,62 % |
Nettoindtægt | 749,54 mio. | -33,86 % |
Overskudsgrad | 17,48 | -34,51 % |
Earnings per share | — | — |
EBITDA | 1,24 mia. | -13,32 % |
Effektiv afgiftssats | 11,36 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
| (CNY) | jun. 2024info | År til år-ændring |
|---|---|---|
Kontanter og korttidsinvesteringer | 9,53 mia. | 9,60 % |
Samlede aktiver | 56,11 mia. | 7,60 % |
Samlede passiver | 11,46 mia. | -12,46 % |
Samlet egenkapital | 44,64 mia. | — |
Shares outstanding | 4,15 mia. | — |
Kurs/indre værdi | 0,38 | — |
Afkast af aktiver | 4,05 % | — |
Afkast af kapital | 4,62 % | — |
Pengestrøm
Nettoændring i likviditet
| (CNY) | jun. 2024info | År til år-ændring |
|---|---|---|
Nettoindtægt | 749,54 mio. | -33,86 % |
Pengestrøm fra drift | 651,06 mio. | -52,65 % |
Pengestrøm fra investering | -191,26 mio. | 75,93 % |
Pengestrøm fra finansiering | -737,79 mio. | -684,70 % |
Nettoændring i likviditet | -258,16 mio. | -153,79 % |
Fri pengestrøm | 350,65 mio. | 52,56 % |
Om
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Administrerende direktør
Grundlagt
2010
Website
Ansatte
12.435
